Robotics in aseptic manufacturing: what Annex 1 expects
By QLogix · Published · 3 min read
The revised EU GMP Annex 1 names robotic systems, with isolators and RABS, as technologies to consider for protecting sterile products. Taking the operator out of the critical zone removes the largest contamination source and moves the quality work to design, software and data.
- Revised EU GMP Annex 1 came into operation.
- 25 Aug 2023
- Where Annex 1 names robotic systems among technologies to consider.
- Section 2.1
- Gloves on a gloveless robotic isolator: no direct human intervention in the critical zone.
- 0
Key takeaways
- Annex 1 does not require robots. It says appropriate technologies, including RABS, isolators and robotic systems, should be considered to increase the protection of the product.
- People are the main source of microbial contamination in aseptic processing, which is why removing interventions is the strongest control available.
- A robotic line still needs a contamination control strategy, environmental monitoring and aseptic process simulation.
- The robot's software and recipes are GMP computerised systems, validated and kept under change control.
What does Annex 1 say about robotics?
The revised Annex 1, Manufacture of Sterile Medicinal Products, was published in August 2022 and came into operation on 25 August 2023, with one provision on lyophilizer loading following a year later. Section 2.1 says that the use of appropriate technologies, giving restricted access barrier systems (RABS), isolators, robotic systems, rapid or alternative methods and continuous monitoring systems as examples, should be considered to increase the protection of the product from potential extraneous sources of contamination.
The annex treats barrier technology as the expected direction. It describes RABS and isolators as beneficial in assuring the required conditions and minimizing microbial contamination from direct human interventions in the critical zone, and asks that alternative approaches be justified.
Annex 1 revision dates
Aug 2022Published
Revised Annex 1 published
Adds the contamination control strategy and quality risk management throughout.
25 Aug 2023In force
Comes into operation
Applies to the manufacture of sterile medicinal products.
25 Aug 2024In force
Point 8.123 applies
The provision on lyophilizer loading and unloading, given an extra year.
How do barrier and robotic systems compare?
Each step along this range reduces how often a person reaches into the zone where sterile product is exposed. A gloveless robotic isolator removes the glove ports altogether: format parts, components and filled units are handled by the robot, and the enclosure stays closed from decontamination to the end of the batch.
Operator access to the critical zone, by technology
| Technology | Operator access during the batch | Main contamination control | What quality has to watch |
|---|---|---|---|
| Conventional cleanroom filling | Gowned operators beside the line | Gowning, aseptic technique, airflow | Intervention counts, operator qualification |
| RABS | Through glove ports; doors closed in operation | Physical barrier and airflow | Glove integrity, door-open events |
| Isolator | Through glove ports only | Closed enclosure with automated bio-decontamination | Decontamination cycle, leak and glove testing |
| Gloveless robotic isolator | None | Closed enclosure, robotic handling | Robot recipes, software changes, fault recovery |
What changes for contamination control?
- The contamination control strategy has to cover the robot itself: surfaces that can be cleaned and decontaminated, materials compatible with vaporized hydrogen peroxide, and particles generated by its movement.
- Robot paths are designed so the arm does not pass over open containers and disturb first air.
- Environmental monitoring continues. With no operator present, sampling plates and probes have to be placed and removed by the robot or by design.
- Aseptic process simulation covers the routine robot operations and the interventions that remain, such as fault recovery.
- Fault handling is defined in advance: which stoppages the robot recovers from, which require the enclosure to be opened, and what happens to the product exposed at that moment.
How are the robot and its software validated?
A filling robot is equipment and a computerised system at once. Its qualification covers the mechanical side, and its software, recipes and vision systems fall under Annex 11 in the EU and the equivalent expectations elsewhere. A risk-based approach fits well: a recipe parameter that sets fill volume or stopper placement is high risk and gets scripted testing, while a screen that only displays status does not.
Where machine vision or machine learning is added, for example to inspect containers or guide the arm, the model needs its own evidence: a defined intended use, test data kept apart from training data, and control over changes.
What does the quality unit decide?
- Batch disposition stays with the quality unit. A robotic line produces more data per batch and the same decision.
- Excursions and alarms are reviewed by people, with the assessment recorded.
- Changes to recipes, paths and software go through change control with an impact assessment.
- The data the line generates, from particle counts to torque curves, is reviewed for trends, which is where early signals of drift appear.
Common questions
Does EU GMP Annex 1 require robotics?
No. Section 2.1 says appropriate technologies such as RABS, isolators and robotic systems should be considered to increase the protection of the product. The annex expects barrier technology to be used or an alternative to be justified, and leaves the choice to the manufacturer's contamination control strategy.
Does a robotic filling line still need media fills?
Yes. Aseptic process simulation remains required. It covers the routine robotic operations and any interventions that remain, including recovery from faults.
When did the revised Annex 1 take effect?
The revised Annex 1 came into operation on 25 August 2023. Point 8.123, on lyophilizer loading and unloading, applied from 25 August 2024.
Sources
- European Commission: EU GMP Annex 1, Manufacture of Sterile Medicinal Products (August 2022)
- European Commission: stakeholder consultation on EudraLex Volume 4, Chapter 4, Annex 11 and new Annex 22
This article is general information for quality and regulatory professionals. It is not regulatory or legal advice. Check the source documents for their current status before acting on them.
More from the blog
- AI in quality · 12 October 2026FDA's seven-step credibility framework for AI, in plain termsFDA's draft guidance asks sponsors to show that an AI model is credible for a specific context of use. The effort scales with model risk: how much the model's output drives the decision, and how serious a wrong decision would be.
- Manufacturing science · 12 October 2026AI in drug manufacturing: where FDA stands and what to build forFDA has no final guidance written only for AI in drug manufacturing. It has a 2023 discussion paper naming five open areas and a 2025 draft framework that covers manufacturing models. Together they show what a process model has to prove.
- Medical devices · 12 October 2026AI-enabled medical devices: what FDA's list and guidance showFDA's public list counted 1,614 AI-enabled medical devices through June 2026, about three in four of them in radiology. Two documents shape how they are built and changed: the final guidance on predetermined change control plans and the draft guidance on lifecycle management.